Anaptysbio (ANAB) Interest Expenses (2016 - 2026)
Anaptysbio's (ANAB) quarterly Interest Expenses came in at $20.8 million in Q1 2026, up 15.1% YoY from $18.1 million in Q1 2025, and up 136.6% on a QoQ basis from -$56.9 million in Q4 2025.
Anaptysbio (ANAB) Interest Expenses (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Interest Expenses data on file, last reported at $20.8 million in Q1 2026.
- Quarterly Interest Expenses rose 15.1% year-over-year to $20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.1 million (down 59.11% YoY) and the FY2025 annual result came in at $180.4 million, down 3.61% from the prior year.
- Interest Expenses grew to $20.8 million in Q1 2026, from -$56.9 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $68.5 million in Q3 2025 to a low of -$56.9 million in Q4 2025.
- A 5-year average of $18.8 million and a median of $20.2 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses sank 405.31% — and 2024, when it surged 2462.98%.
- Tracing ANAB's Interest Expenses over 5 years: stood at $584000.0 in 2022, then slumped by 405.31% to -$1.8 million in 2023, then surged by 2462.98% to $42.1 million in 2024, then slumped by 235.11% to -$56.9 million in 2025, then surged by 136.6% to $20.8 million in 2026.
- The last three Interest Expenses figures came in at $20.8 million (Q1 2026), -$56.9 million (Q4 2025), and $68.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 20.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.83 Mn |
| Mar 31, 2026 | 20.83 Mn |
| Dec 31, 2025 | -56.93 Mn |
| Dec 31, 2025 | -56.93 Mn |
| Sep 30, 2025 | 68.50 Mn |
| Sep 30, 2025 | 68.50 Mn |
| Jun 30, 2025 | 19.65 Mn |
| Jun 30, 2025 | 19.65 Mn |
| Mar 31, 2025 | 18.10 Mn |
| Mar 31, 2025 | 18.10 Mn |
| Dec 31, 2024 | 42.13 Mn |
| Dec 31, 2024 | 42.13 Mn |
| Sep 30, 2024 | 59.99 Mn |
| Sep 30, 2024 | 59.99 Mn |
| Jun 30, 2024 | 19.62 Mn |
| Jun 30, 2024 | 19.62 Mn |
| Mar 31, 2024 | 20.23 Mn |
| Mar 31, 2024 | 20.23 Mn |
| Dec 31, 2023 | -1.78 Mn |
| Dec 31, 2023 | -1.78 Mn |